The peptide research blog

Most abandoned peptide orders don't die on the product page. They die at the payment step, where a vague decline leaves you unsure whether you were charged. Here is every payment rail Real Peptides runs, what each one does, and what happens when one fails.

One of these molecules hits two receptors. The other hits three, and that third arm changes which endpoints its trials were even built to detect. Here is what the published literature and the public trial registry actually say about each program as of October 2026.

Two sealed vials can carry the same name and hold measurably different material. The name on a Cerebrolysin label is not the specification. The specification is the stated concentration, the country of manufacture, the lot number, and the certificate of analysis that matches it.

Most people assume the fridge is the safer choice. The manufacturer's label says otherwise: 20 to 25 C, controlled room temperature. What actually governs shelf life is the preservative, the printed expiry, and the clock that starts the moment the seal is punctured.

LL-37 isn't a designer research compound. It's a 37-residue fragment the human body cleaves out of its own precursor protein, and it's the only cathelicidin humans produce. That single fact explains why most of what gets written about it online is wrong.

Clearing senescent cells is not automatically beneficial, and the FOXO4-DRI literature contains the counterexample to prove it. This research overview covers the molecule's chemistry, the published studies behind it, what remains unknown about its pharmacokinetics, and how laboratories verify a vial before it ever reaches the bench.

The most important document in tesofensine's published record isn't a trial result. It's a journal expression of concern. Here is what the literature actually reports about mechanism, findings, adverse-effect reporting, pharmacokinetics, and how a research vial gets verified.

Oxytocin's best-documented biology isn't emotional at all. It's mechanical: smooth muscle contraction driven by a single G protein-coupled receptor. This page separates what the peer-reviewed literature actually reports from what headlines claim, and covers the purity and identity data a laboratory should demand before accepting a vial.

Few research peptides have a preclinical record and a clinical record that disagree this sharply. The mouse data looked strong, the human obesity program never reached approval, and the detection science turned out to be the most interesting part of the whole story.

Three peptides in one vial sounds like three times the evidence. It isn't. The published record behind this blend is overwhelmingly GHK-Cu literature, and almost none of it is human work. Here is what is documented, what is assumed, and where the data stops.

The name came from a comic book character, not a clinical trial. Behind the branding sit two peptides with very different mechanisms, a preclinical evidence base, and almost no published human pharmacokinetic data. Here is what the literature actually reports.

Search PubMed for Adamax and you will find nothing indexed under that name. Every mechanistic claim attached to it is borrowed from Semax research in rodents. This page separates what the literature actually reports from what suppliers extrapolate, and explains how a vial gets verified.

The 344 in Follistatin-344 isn't a strength or a concentration. It's an amino acid count describing a precursor protein that never circulates in that form. Understanding that single structural fact explains most of the mislabelling, misreading, and misattributed study results in this corner of the literature.

Melatonin is not a sedative and not a peptide, despite being sold under both labels. It is a darkness signal built from tryptophan, acting on two G protein-coupled receptors. Here is what the published literature actually reports about its mechanism, pharmacokinetics and open questions.

Erythropoietin's most interesting signalling may have nothing to do with red blood cells. ARA-290 (cibinetide) is the 11-amino-acid peptide built to prove it, binding the innate repair receptor without touching haematocrit. Here is what the peer-reviewed literature reports, and how a laboratory verifies a vial before it reaches a bench.

The most misunderstood fact about MK-677 is that it isn't a peptide at all. It's a non-peptide small molecule that happens to bind the ghrelin receptor, which is the only reason it sits in peptide catalogues. Here's what the published record actually says.

Retatrutide is not simply tirzepatide with one extra receptor attached. Adding glucagon receptor agonism changes the pharmacological category entirely, and that single structural decision is why the published trial record reads so differently from every other metabolic peptide studied in the last decade.

Nearly everything written online about Cartalax borrows its evidence from a different molecule. The tripeptide AED has almost no indexed literature of its own, while the tetrapeptide AEDG has some. That distinction changes how a laboratory should read every claim made about this compound.

Most of what circulates about this tripeptide comes from vendor copy, not from the indexed record. The actual literature is narrower, older and almost entirely preclinical. Here is what the research describes, how lot purity is documented, and what to verify before procurement.

Sleep is not a marketing angle in this literature — it is a measurement artifact. Growth hormone pulsatility and slow-wave sleep are intertwined in human physiology, so sleep variables show up in secretagogue studies by default. For a wholesale buyer, though, the real question is sourcing, not science.

Pre-cycle and post-cycle are administration terms — which means a research supplier that answers them is telling you something about its compliance, not its expertise. The sourcing comparison that matters for a tesamorelin and ipamorelin catalog is blended vial versus two separately tested single-compound vials.

In growth hormone secretagogue studies, the feeding state of the model can move results more than the compound itself — which is why diet is a controlled variable, not a footnote. For a wholesale buyer, a blended vial adds a second problem: verifying two peptides on one chromatogram.

A blended vial can hide what a single-compound vial has to prove. Put two growth hormone secretagogues in one container and standard purity reporting gets harder to read — which is exactly why wholesale buyers should ask how a blend was tested before it ever reaches their shelves.

Blending two secretagogues into one vial does not simplify your sourcing — it doubles the analytical work and halves what a single chromatogram can tell you. For wholesale buyers, stress and stability questions start with how the material was characterized, not how it is stored.

A single 99% purity figure on a two-peptide vial tells you almost nothing — purity and ratio are entirely different questions, and one chromatogram can obscure both. Here is the analytical panel a wholesale buyer should insist on before any blended research vial goes into stock.

A blend vial is not simply two compounds in one bottle — it is a single certificate of analysis covering two separate identities, and that changes what your data can actually demonstrate. The bloodwork tracked in growth hormone axis research is only as interpretable as the material behind it.

A pre-mixed two-peptide vial is not a convenience — it is an analytical problem. One chromatogram has to resolve two different molecules and report purity for each, and when a result drifts out of spec, nothing on the paperwork tells you which input failed. Here is what that means for your catalog.

A blend is not two peptides sharing a vial — it is one lot with one shared stability profile, and most wholesale documentation problems start right there. Hydration notes are really sourcing notes: solvent, concentration, cold chain, and the certificate of analysis standing behind the lot number.

The hardest problem in imaging-based secretagogue research isn't the scanner — it's the vial. A pre-mixed blend makes it structurally impossible to attribute any imaging signal to one compound, and inconsistent lots quietly corrupt longitudinal data before the first scan is ever read.

A blended vial looks like convenience and reads like a verification problem. The inflammation-marker literature behind tesamorelin and ipamorelin belongs to each compound on its own, which is exactly why single-compound vials with batch-matched COAs are easier to defend to your own buyers.

A pre-mixed tesamorelin and ipamorelin vial is harder to verify than two separate ones — overlapping analytical signals blur the purity picture every HPLC report is supposed to make clear. For a wholesale buyer, that single technical detail usually decides what belongs on the shelf and what does not.

A hormone panel cannot tell you whether a shift came from the compound or from the vial it arrived in. Undocumented purity, net peptide content and lot-to-lot variance all land in the same dataset as the signal. Sourcing is a measurement decision before it is a purchasing one.

A blend's 'performance metrics' have nothing to do with how it performs in anyone. For a research-use-only compound, performance is purity, identity, net peptide content and a verified ratio — numbers that live on a batch certificate. If a supplier leads with outcomes instead of lot numbers, that is your answer.

A blend is not two peptides in one vial — it is one analytical problem with two answers. If a supplier's certificate reports a single purity number for a two-compound product, it has told you almost nothing. Here is what a buyer should demand instead.

A blended vial is harder to verify than two single-compound vials, not easier — one chromatogram has to resolve and quantify both peptides before the number on the label means anything. For wholesale buyers, that analytical problem matters far more than any cognitive-endpoint headline.

A blended vial can obscure the one thing a wholesale buyer most needs: a per-compound purity figure tied to a lot number. Tesamorelin and ipamorelin appear side by side throughout the secretagogue literature, but how they arrive on your shelf decides whether you can verify what is actually in them.

The hardest part of a tesamorelin and ipamorelin blend study usually isn't the sensor array — it's the vial. Continuous wearable data surfaces lot-to-lot variability that a weekly checkpoint would have hidden entirely, which turns supplier documentation into a study-design decision rather than a purchasing one.

Apple Health can chart a step count, but it cannot tell you whether the vial in your inventory is 99% pure. Tesamorelin and ipamorelin research questions live in the COA, not the dashboard — and that difference decides which wholesale supplier you trust.

A blend vial is harder to verify than two single-compound vials, not easier. Pooling tesamorelin and ipamorelin into one container collapses part of the analytical trail a COA depends on — and heart rate variability is exactly the kind of soft, noisy endpoint that amplifies sourcing uncertainty rather than hiding it.

The search pairing a tesamorelin + ipamorelin blend with WHOOP data isn't describing a product — it's describing an end-user habit that most wholesale catalogs can't answer with one SKU. For buyers, the verification question matters more than the blend: what does the batch COA actually show?

A blended vial is harder to verify than two single-compound vials, not easier. DEXA endpoints dominate the published literature on growth-hormone-axis compounds, but a scan number means nothing if the material behind it was never identity-tested component by component. Here is what wholesale buyers check first.

A blend saves a line on your purchase order and costs you the ability to verify what is actually in the vial. Tesamorelin and ipamorelin act through different receptors, and no wearable dataset — Oura included — turns a sourcing decision into evidence.

The search term pairs two things that cannot legitimately touch: a research-use-only compound pair and a consumer wearable data stream. No supplier can bridge them — and the buyers who understand why tend to ask much sharper questions about batch documentation, blend policy and fulfillment.

A sauna is one of the worst neighbors a peptide inventory can have. Heat and steam degrade lyophilized compounds long before anyone notices a problem, and no certificate of analysis covers what happened after the box arrived. Here's what wholesale buyers should actually verify.

A blended vial is not simply two peptides sharing a container — the two molecules do not necessarily share a stability profile, which is why cold handling questions get harder, not easier, when compounds are combined. For wholesale buyers, that makes documentation the real purchasing decision.

A glucose time-series tells you nothing if you can't prove what was in the vial. In blended growth hormone secretagogue research, continuous glucose monitor notes are only as credible as the lot behind them — which makes sourcing, not instrumentation, the first variable a wholesale buyer has to control.

Alcohol shows up twice in tesamorelin and ipamorelin research — once as a documented confounder in growth-hormone study design, and again as solvent chemistry in the vial. Most wholesale buyers only think about the second one. The sourcing decisions that follow are different for each.

Fasting isn't a protocol in peptide research — it's a variable that can swamp a dataset when nobody controls it. Growth hormone secretagogue work is unusually sensitive to feeding state, which is exactly why batch-to-batch consistency matters as much as study design for anyone buying these compounds wholesale.

A blended vial looks like a convenience. In research sourcing it is often the opposite — one certificate of analysis covering two compounds tells you less than two certificates covering one each. Cannabis exposure then adds a second layer of questions, one biological and one commercial.

A temperature excursion rarely shows up as a cloudy vial — degraded peptide usually looks identical to intact peptide. That is why research material moving between sites needs documentation and handling discipline rather than a visual check at the receiving end.

Time zones rarely change the science of a growth-hormone-axis study — they change whether your second site receives vials from the same lot as your first. The hard part of distributed peptide research is paperwork, cutoffs, and carrier calendars, not chemistry.

The flight itself is rarely what degrades a peptide shipment — the hours it spends on a tarmac or in a customs queue are. For wholesale buyers evaluating tesamorelin and ipamorelin material, long-haul transit risk is a documentation problem before it is ever a temperature problem.

A pre-mixed vial looks like convenience and reads like a verification problem: a single purity figure on a two-peptide mixture tells you less than two separate certificates do. Caffeine, meanwhile, is a study-design variable in growth hormone-axis work — which makes it a sourcing question for buyers, not a protocol one.

A sealed lyophilized vial doesn't care about the view — but the cargo hold it crossed and the dry, thin air it lands in both leave marks. For buyers stocking tesamorelin and ipamorelin at elevation, altitude is a logistics and documentation problem long before it is a science one.

Pairing two growth-hormone-axis compounds in a study is the easy part. The hard part is that a pre-mixed blend destroys your ability to prove what is actually in the vial — which is why serious sourcing starts with single-compound lots and per-batch certificates of analysis.

Heat is not the only enemy — a vial that freezes, thaws, and sweats on a loading dock can be compromised in winter just as easily as in July. For wholesale buyers, climate risk is decided before the box ships: sourcing distance, packaging, and what the COA actually documents.

The thyroid question around tesamorelin and ipamorelin blends isn't really a formulation question — it's a sourcing question. Blended vials hide what single-compound vials reveal, and the only way to know what is in one is a batch-level COA you can read yourself.

A blended vial looks like a convenience and behaves like a verification problem. Two actives in one container means one certificate of analysis has to carry twice the work — and the adrenal-axis questions researchers ask about these compounds only matter if you can prove what is actually in the vial.

A two-peptide vial is not two peptides' worth of certainty. Pre-mixing tesamorelin and ipamorelin makes per-compound purity, identity, and stability harder to verify than buying either one alone — which is why the blend question is a sourcing question before it is a science question.

A blended vial is not two COAs in one bottle. Co-formulating tesamorelin and ipamorelin makes purity harder to attribute, not easier — which is exactly why serious research buyers tend to source each compound separately and verify them on their own batch documentation.